Personalized Depression Treatment Supported by Mobile Sensor Analytics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-04

Study Completion Date

2025-06-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current best practice guidelines for treating depression call for close monitoring of patients, and periodically adjusting treatment as needed. This present study seeks to develop and investigate an innovative digital system, DepWatch, that leverages mobile health technologies and machine learning tools to provide clinicians objective, accurate, and timely assessment of depression symptoms to assist with their clinical decision making process. Specifically, DepWatch collects sensory data passively from smartphones and wristbands, without any user interaction, and uses simple user-friendly interfaces to collect ecological momentary assessments (EMA), medication adherence and safety related data from patients. The collected data will be fed to machine learning models to be developed in the project to provide weekly assessment of patient symptom levels and predict the trajectory of treatment response over time. The assessment and prediction results are then presented using a graphic interface to clinicians to help them make critical treatment decisions. The main question the present clinical trial aims to answer are as follows:

1. Feasibility of the digital tool, DepWatch, to assist clinicians in depression treatment and inform their clinical decision process
2. Effectiveness of the digital tool, DepWatch, to improve depression treatment outcomes All study participants will carry the DepWatch app on their smartphones and wear a Fitbit provided by the study team during the study period. They will also complete brief questionnaires via the app at specific time intervals throughout the study period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Remote Evaluation and Alerting for Collaborative Health (REACH) in Depression

NCT07174557

Depression Major Depressive Disorder

NOT_YET_RECRUITING NA

Digital Phenotypes for Predicting Depression

NCT07151846

Depression - Major Depressive Disorder Depression Bipolar Bipolar Disorder (BD) +1 more

ENROLLING_BY_INVITATION

Detection Algorithm for Recurrence or Relapse of Depression Thanks to a Smartwach

NCT06789822

Depressive Disorder Depressive Disorder, Major Depressive Disorder Depressive Disorder Not Otherwise Specified (NOS)

ACTIVE_NOT_RECRUITING NA

Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis

NCT02330679

Major Depressive Disorder

UNKNOWN PHASE4

Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application

NCT03678194

Depression Psychiatric Disorder Brain Diseases +2 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Two groups of participants (64 per group) will be enrolled and will participate in the study over a 3 month period . Both will receive standard of care depression treatment with their respective providers in the clinic. Both groups will undergo standard depression assessment using depression questionnaires as well as behavioral assessments using a mobile health (mHealth) tool 'DepWatch' developed by the study team in the phase I of the study. Study clinicians will receive weekly behavioral assessment reports for participants enrolled in the first 'experimental' group and will not receive such reports for the second 'control' group

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

There is no masking

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental

For this group of participants: The study clinicians will receive the weekly depression and behavioral assessment reports generated by the mHealth tool 'DepWatch' via a secure clinician portal

Group Type EXPERIMENTAL

A mobile Health (mHealth) tool called 'DepWatch'

Intervention Type OTHER

The mobile Health (mHealth) tool 'DepWatch' developed by the study team consists of the DepWatch app that is uploaded on participant's smart phones with their consent and a Fitbit provided to the participants

Control

For this group of participants: The study clinicians will NOT receive the weekly depression and behavioral assessment reports generated by the mHealth tool 'DepWatch'

Group Type OTHER

A mobile Health (mHealth) tool called 'DepWatch'

Intervention Type OTHER

The mobile Health (mHealth) tool 'DepWatch' developed by the study team consists of the DepWatch app that is uploaded on participant's smart phones with their consent and a Fitbit provided to the participants

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

A mobile Health (mHealth) tool called 'DepWatch'

The mobile Health (mHealth) tool 'DepWatch' developed by the study team consists of the DepWatch app that is uploaded on participant's smart phones with their consent and a Fitbit provided to the participants

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 year or older
* Moderate level of depression as defined by a score of ≥ 11 on the 16 item Quick Inventory of Depressive Symptomatology (QIDS) self-report questionnaire
* Initiating a pharmacological treatment for depression as monotherapy or adjunctive treatment or reporting a dose increase with their existing depression treatment.

Exclusion Criteria

* Diagnosis of a primary psychotic disorder such as schizophrenia or schizoaffective disorder
* Currently active substance use disorder (within 1 month of enrollment) dominating clinical scenario
* Other clinically significant medical of psychiatric conditions that may adversely affect participants' study participation and/or affect their adherence to study protocol (as determined by study clinician) e.g., significant cognitive deficits

Eligible Sex

ALL

Accepts Healthy Volunteers

No